Literature DB >> 10997623

Thyroid and lipid metabolism.

E Pucci1, L Chiovato, A Pinchera.   

Abstract

Thyroid hormones influence all major metabolic pathways. Their most obvious and well-known action is an increase in basal energy expenditure obtained acting on protein, carbohydrate and lipid metabolism. With specific regard to lipid metabolism, thyroid hormones affect synthesis, mobilization and degradation of lipids, although degradation is influenced more than synthesis. The main and best-known effects on lipid metabolism include: (a) enhanced utilization of lipid substrates; (b) increase in the synthesis and mobilization of triglycerides stored in adipose tissue; (c) increase in the concentration of non-esterified fatty acids (NEFA); and (d) increase of lipoprotein-lipase activity. While severe hypothyroidism is usually associated with an increased serum concentration of total cholesterol and atherogenic lipoproteins, the occurrence of acute myocardial infarction (AMI) in hypothyroid patients is not frequent. However, hypothyroid patients appear to have an increased incidence of residual myocardial ischemia following AMI. Even in subclinical hypothyroidism, which is characterized by raised serum TSH levels with normal serum thyroid hormone concentrations, mild hyperlipidemia is present and may contribute to an increased risk of atherogenesis. Prudent substitution therapy with L-thyroxine is indicated in patients with both overt and subclinical hypothyroidism, with or without angina, to counteract the cardiovascular risk resulting from hyper-dyslipidemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997623     DOI: 10.1038/sj.ijo.0801292

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  78 in total

1.  Relationship between serum TSH level with obesity and NAFLD in euthyroid subjects.

Authors:  Jiaoyue Zhang; Hui Sun; Lulu Chen; Juan Zheng; Xiang Hu; Suxing Wang; Ting Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

2.  Prevalence of hypothyroidism in nonalcoholic fatty liver disease in patients attending a tertiary hospital in western India.

Authors:  Pathik Parikh; Aniruddha Phadke; Prabha Sawant
Journal:  Indian J Gastroenterol       Date:  2015-04-16

Review 3.  Interactions of metabolic hormones, adipose tissue and exercise.

Authors:  Robert G McMurray; Anthony C Hackney
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

4.  Development of metabolic syndrome after bilateral total thyroidectomy despite the L-t4 replacement therapy: A prospective study.

Authors:  İsmail Zihni; Volkan Soysal; Adam Uslu; Baha Zengel; Gökalp Okut; Ahmet Aykas; Ali Duran; Erhan Tatar
Journal:  Turk J Surg       Date:  2018-08-28

5.  Candidate agents for papillary thyroid cancer identified by gene expression analysis.

Authors:  Wei Zhu; Chen Li; Zhilong Ai
Journal:  Pathol Oncol Res       Date:  2013-03-22       Impact factor: 3.201

Review 6.  Lipid lowering effects of iodothyronines: In vivo and in vitro studies on rat liver.

Authors:  Laura Vergani
Journal:  World J Hepatol       Date:  2014-04-27

7.  Nonalcoholic Fatty Liver Disease Is Not Associated with Thyroid Hormone Levels and Hypothyroidism: A Systematic Review and Meta-Analysis.

Authors:  Veeravich Jaruvongvanich; Anawin Sanguankeo; Sikarin Upala
Journal:  Eur Thyroid J       Date:  2017-01-21

8.  Burst-like control of lipolysis by the sympathetic nervous system in vivo.

Authors:  Katrin Hücking; Marianthe Hamilton-Wessler; Martin Ellmerer; Richard N Bergman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

9.  Dyslipidaemic changes in women with subclinical hypothyroidism.

Authors:  N Karthick; K Dillara; K N Poornima; A S Subhasini
Journal:  J Clin Diagn Res       Date:  2013-10-05

10.  Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.

Authors:  M Ozkaya; M Sahin; E Cakal; F Yuzbasioglu; K Sezer; M Kilinc; S Simsek Imrek
Journal:  J Endocrinol Invest       Date:  2009-05-15       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.